GeminIQ Website Logo

Viewing BRTX free

Subscribe for full history, 50+ metrics, screener, watchlist...

BioRestorative Therapies, Inc.

BRTX

Companies in Services-Misc Health & Allied Services, NEC

BioRestorative Therapies, Inc. (BRTX) — SEC Financial Statements & Analysis

BioRestorative Therapies, Inc. (BRTX) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
321211121122
Marketable Securities Current
0146810121215101010
Accounts Receivable Net Current
000000000000
Prepaid Expense And Other Assets Current
000000000000
Deferred Offering Costs
------0-----
Assets Current
4358911141517111312
Property Plant And Equipment Net
000000000000
Operating Lease Right Of Use Asset
------000000
Intangible Assets Net Excluding Goodwill
111111111111
Deferred Costs
-------00---
Assets
54691012151618131413
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current
111110000000
Other Accrued Liabilities Current
111001------
Accrued Liabilities Current
-----1100110
Deferred Revenue
-------0----
Operating Lease Liability Current
------000000
Derivative Liabilities Current
-123333432--
Contract With Customer Liability Current
----0-------
Liabilities Current
243444553311
Operating Lease Liability Noncurrent
----------00
Liabilities
---444553311
Stockholders Equity
Preferred Stock Value
--000-00----
Common Stock Value
000000000000
Additional Paid In Capital
175170169169167164164164163157177174
Retained Earnings Accumulated Deficit
-172-170-167-164-161-156-154-153-149-147-164-161
Stockholders Equity
30256910111510113
Liabilities And Stockholders Equity
54691012151618131413
Preferred Stock Par Or Stated Value Per Share
0.010.010.010.010.010.010.010.010.010.010.010.01
Preferred Stock Shares Authorized
202020202020202020202020
Common Stock Par Or Stated Value Per Share
000000000000
Common Stock Shares Authorized
225225225225225225225225225225225225
Common Stock Shares Issued
252724242321212120191920
Shares Outstanding
252724242321212120191920

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026114.40%111.75%----------
20255.56%-9.36%-17.54%8.84%2.04%4.76%-19.57%-11.59%-17.39%-10.91%-35.07%19.09%
202459.83%22.22%40.17%8.51%15.46%10.64%-9.15%-8.54%45.12%-3.31%-11.05%-7.18%
2023----11.20%-30.89%-27.41%0.08%-4.93%57.43%-10.71%-7.86%45.00%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
2.35
0.84
1.37
2.07
2.24
2.97
2.95
2.82
4.86
4.37
13.51
14.82
Quick Ratio
2.23
0.80
1.31
2.01
2.19
2.91
2.90
2.76
4.77
4.25
13.17
14.32
Working Capital
2.19M
-586.03K
1.27M
3.93M
5.17M
7.40M
8.93M
9.68M
13.32M
8.78M
11.67M
11.23M
Leverage & Debt
Debt to Equity
0.53
10.44
1.56
0.76
0.68
0.44
0.46
0.49
0.24
0.26
0.09
0.34
Interest Coverage TTM
-
-
-
-
-
-
-
-
-
-
-
-630.60
Debt Ratio
0.35
0.91
0.61
0.43
0.40
0.31
0.31
0.33
0.19
0.21
0.07
0.07
Efficiency & Turnover
Asset Turnover TTM
0.05
0.04
0.04
0.05
0.03
0.03
0.03
0.01
0.01
0.01
0.01
0.01
Days Sales Outstanding TTM
19.53
103.45
84.92
12.79
28.01
94.53
98.90
54.93
62.26
44.19
118.16
58.23
Receivables Turnover TTM
18.69
3.53
4.30
28.55
13.03
3.86
3.69
6.65
5.86
8.26
3.09
6.27
Per Share Metrics
Diluted EPS TTM
-0.62
-0.79
-0.69
-0.61
-0.72
-0.58
-0.59
-0.23
-0.41
-0.82
-0.58
-1.42
Free Cash Flow Per Share TTM
-0.67
-0.61
-0.59
-0.55
-0.53
-0.54
-0.47
-0.44
-0.32
-0.31
-0.29
-0.30
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Margin Metrics
Gross Profit Margin TTM
92.09%
93.37%
93.34%
94.51%
92.08%
93.00%
101.74%
114.25%
120.94%
-
-
-
Operating Profit Margin TTM
-3,975.00%
-4,350.05%
-3,785.07%
-2,162.91%
-3,133.88%
-2,881.59%
-3,205.76%
-7,411.36%
-9,064.17%
-10,439.49%
-12,812.59%
-14,153.50%
Net Profit Margin TTM
-3,089.55%
-3,959.40%
-3,304.77%
-1,771.91%
-3,093.59%
-2,239.25%
-2,558.95%
-2,175.50%
-3,657.78%
-7,145.20%
-5,521.34%
-12,928.31%
Growth Metrics
Net Revenue Growth (1Y)
-8.47%
-10.30%
1.70%
247.62%
161.54%
175.03%
189.55%
35.49%
10.66%
21.70%
7.51%
28.37%
Net Income Growth (1Y)
-8.59%
58.61%
31.34%
183.13%
121.20%
-13.81%
34.20%
-77.20%
-64.90%
-21.21%
-79.19%
-51.25%
EPS Growth (1Y)
-13.82%
36.93%
17.01%
163.08%
164.87%
17.08%
88.82%
-67.27%
-60.88%
-18.91%
-80.10%
-54.36%
Valuation Metrics
P/E TTM
-0.44
-1.48
-2.09
-2.72
-2.46
-2.47
-2.93
-8.71
-5.05
-3.52
-5.69
-6.19
P/B
1.59
59.24
11.98
6.01
4.84
2.60
2.83
3.05
1.90
3.67
3.80
38.88
P/S TTM
13.48
58.75
68.95
48.11
76.09
55.37
74.97
189.39
184.75
251.70
314.20
800.25
Market Cap
4.82M
21.13M
26.44M
29.12M
29.75M
22.20M
28.26M
32.97M
27.62M
36.70M
40.91M
102.83M
Enterprise Value
1.71M
19.62M
25.83M
27.56M
28.52M
21.66M
26.77M
30.72M
26.46M
35.81M
38.47M
101.05M
Calculated Values
Free Cash Flow TTM
-11.90M
-10.91M
-10.77M
-9.63M
-8.83M
-8.34M
-7.63M
-7.07M
-6.48M
-6.60M
-6.60M
-6.89M
Net Debt
-3.11M
-1.51M
-602.44K
-1.56M
-1.23M
-547.89K
-1.49M
-2.25M
-1.16M
-884.38K
-2.44M
-1.78M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2024-10-28Sale
Owner: Broadrick, Dale
Title: -
Shares: 1,112
Price/Share: $1.58
Value: $1,756.96
Shares Owned: 445,933
Relationship: TenPercentOwner
Ownership: Direct
2024-04-09Purchase
Owner: Silva, Francisco
Title: VP of Research and Development
Shares: 6,600
Price/Share: $1.25
Value: $8,250.00
Shares Owned: 155,759
Relationship: Director,Officer
Ownership: Direct
2024-02-09Purchase
Owner: Broadrick, Dale
Title: -
Shares: 86,041
Price/Share: $1.32
Value: $113,574.12
Shares Owned: 477,972
Relationship: TenPercentOwner
Ownership: Indirect
2024-02-07Purchase
Owner: Broadrick, Dale
Title: -
Shares: 36,374
Price/Share: $1.38
Value: $50,196.12
Shares Owned: 363,419
Relationship: TenPercentOwner
Ownership: Direct
2023-12-01Sale
Owner: Broadrick, Dale
Title: -
Shares: 250
Price/Share: $1.88
Value: $470.00
Shares Owned: 327,045
Relationship: TenPercentOwner
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
3.82%
Inst. Shares: 677,096
Shares Outstanding: 17,727,747
2025-12-31
3.64%
Inst. Shares: 654,322
Shares Outstanding: 17,986,230
2025-09-30
3.90%
Inst. Shares: 710,322
Shares Outstanding: 18,232,344
2025-06-30
2.69%
Inst. Shares: 470,692
Shares Outstanding: 17,480,764
2025-03-31
2.76%
Inst. Shares: 461,514
Shares Outstanding: 16,714,286

Research Faster.
Invest Smarter.

BioRestorative Therapies, Inc. (BRTX) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 50+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.